Find and Pitch Jounalists, Get Your Story Covered

Tags: NICE\darzalez\lenalidomide multiple myeloma,smoldering multiple myeloma,immunotherapy,hematology

	Profile	Recent Articles on Subject
1	1387865 PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	NICE nod for Darzalex with lenalidomide and dexamethasone - about 1 year ago
2	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts Biologic License Application for Biosimilar Denosumab - 16 days ago FDA Grants Orphan Drug, Fast Track Designation to RLS-0071 for aGVHD - 3 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 3 months ago FDA Grants Priority Review for Asciminib for Chronic Myeloid Leukemia - 4 months ago Brentuximab Vedotin Shows 37% Reduction in Risk of Death for DLBCL - 5 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 8 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 11 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 12 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - about 1 year ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	ERLEADA shows 23% survival benefit over enzalutamide in prostate cancer study - about 1 month ago
4	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago Study: Avoid Completion ALND for Abemaciclib Eligibility in Early Breast Cancer - 3 months ago Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies - 3 months ago Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC - 4 months ago PD-1 Inhibitor Plus Chemotherapy Shows Promising Activity in Rare Lymphoma - 8 months ago A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu - 8 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 9 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - 11 months ago
5	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Priority Review for Durvalumab to Treat Small Cell Lung Cancer - 3 months ago FDA Approves Durvalumab Plus Chemotherapy to Treat Endometrial Cancer - 5 months ago Utidelone Injectable Granted FDA Orphan Drug Designation for Breast Cancer Brain Metastasis - 8 months ago Treatment With Anifrolumab-fnia Shows Promising Rates of Remission for Lupus - about 1 year ago
6	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	'Very Clear Signal' That Survival Improved With Addition of Durvalumab in SCLC - 4 months ago Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 4 months ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 4 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 10 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 10 months ago Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients - 11 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma - 11 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 11 months ago
7	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Brigatinib Makes Its Case for ALK-Positive ALCL in Small Study - 5 months ago FDA Approves New Frontline Regimen for Aggressive ALL - 8 months ago FDA Approves First CAR-T for Chronic Lymphocytic Leukemia - 8 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 11 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - 11 months ago Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder - 11 months ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - 11 months ago MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia - 11 months ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - 11 months ago Lymphoma Drug Copanlisib to Be Pulled From U.S. Market - about 1 year ago Randomized Trial Backs HIF-2a Inhibition in Advanced RCC - about 1 year ago
8	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Grants Accelerated Approval to Zanubrutinib for Relapsed, Refractory Follicular Lymphoma - 8 months ago MONALEESA Pooled Analyses Show Quality of Life Is Maintained in Elderly Patients Receiving Ribociclib, Endocrine Therapy - 11 months ago Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma - about 1 year ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Grants Breakthrough Therapy Designation to Nipocalimab for the Treatment of Rare Disease in Pregnancy - 9 months ago Lutetium Lu 177 Dotatate Reduced Risk of Death By 72% Compared to Comparator in Patients With Advanced GEP-NETs - 10 months ago
10	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard-of-Care Regimen for Previously Unmanaged CLL - 10 months ago Subcutaneous Daratumumab Plus VRd Significantly Improved PFS, Increased Depth of Response in Patients With Newly Diagnosed Multiple Myeloma - 11 months ago Ibrutinib Plus Venetoclax With MRD-Directed Duration of Treatment Is a New Standard of Care Regimen for Previously Untreated CLL - 11 months ago Phase 3 Study Supports Pembrolizumab Plus Lenvatinib as Standard of Care in Patients With Advanced Endometrial Cancer Who Received Prior Platinum Therapy - about 1 year ago

Journalists covering lenalidomide